2021, page-24

I know the Lavender phase 3 trial is double-blind and supposedly there is no way of knowing the results in advance.
And yet with Acadia investing $100 million in the trial, I also so I find it hard to believe they wouldn't be trying to get some sort of early indication of progress.

Of course, there is also the open-label Lilac trial now running in parallel - where it's perhaps more likely that some news may leak out.

Which brings us to this recent Acadia job ad for a director of new product planning
https://job-openings.monster.com/associate-director-new-product-planning-rare-disease-san-diego-california-united-states-us-acadia-pharmaceuticals-inc/68077ef5-909a-4827-b794-83bcaf28f0ef

No doubt the company is being prudent, advertising now just in case Lavender comes up trumps..And yet the way they talk specifically about Trofinetide, it almost seems they are assuming success and that Trofinetide will be approved and will go to market...this job is for a marketing expert, not a scientist.

The job description includes:

• Lead marketing strategy for trofinetide, including audience definition and segmentation, value proposition, branding, positioning, key messages, and promotional material development

• Develops the commercial launch plan for trofinetide in the U.S. market, including brand growth strategies and tactics that target HCPs, patients & caregivers

Read into it what you will.

GLTAH
LO